S
Sara A. Hurvitz
Researcher at University of California, Los Angeles
Publications - 365
Citations - 15800
Sara A. Hurvitz is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 49, co-authored 270 publications receiving 9495 citations. Previous affiliations of Sara A. Hurvitz include University of California, Berkeley & Oklahoma State University Center for Health Sciences.
Papers
More filters
Journal ArticleDOI
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
Jennifer K. Litton,Hope S. Rugo,Johannes Ettl,Sara A. Hurvitz,Anthony Gonçalves,Kyung Hun Lee,Louis Fehrenbacher,Rinat Yerushalmi,Lida A. Mina,Miguel Martin,Henri Roché,Young-Hyuck Im,Ruben G.W. Quek,Denka Markova,Iulia Cristina Tudor,Alison L. Hannah,Wolfgang Eiermann,Joanne L. Blum +17 more
TL;DR: Among patients with advanced breast cancer and a germline BRCA1/2 mutation, single‐agent talazoparib provided a significant benefit over standard chemotherapy with respect to progression‐free survival.
Journal ArticleDOI
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
Shanu Modi,Cristina Saura,Toshinari Yamashita,Yeonhee Park,Sung Bae Kim,Kenji Tamura,Fabrice Andre,Hiroji Iwata,Yoshinori Ito,Junji Tsurutani,Junji Tsurutani,Joohyuk Sohn,Neelima Denduluri,Christophe Perrin,Kenjiro Aogi,Eriko Tokunaga,Seock-Ah Im,Keun Seok Lee,Sara A. Hurvitz,Javier Cortes,Caleb Lee,Shuquan Chen,Lin Zhang,Javad Shahidi,Antoine Yver,Ian E. Krop +25 more
TL;DR: Tastuzumab deruxtecan showed durable antitumor activity in a pretreated patient population with HER2-positive metastatic breast cancer and requires attention to pulmonary symptoms and careful monitoring.
Journal ArticleDOI
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.
Rashmi Krishna Murthy,Sherene Loi,Alicia Okines,Elisavet Paplomata,Erika Hamilton,Sara A. Hurvitz,Nan Lin,Virginia F. Borges,Vandana G. Abramson,Carey K. Anders,Philippe L. Bedard,Mafalda Oliveira,Erik Jakobsen,Thomas Bachelot,Shlomit S. Shachar,Volkmar Müller,Sofia Braga,François Duhoux,Richard Greil,David Cameron,Lisa A. Carey,Giuseppe Curigliano,Karen A. Gelmon,Gabriel N. Hortobagyi,Ian E. Krop,Sibylle Loibl,Mark D. Pegram,Dennis J. Slamon,M Corinna Palanca-Wessels,Luke Walker,Wentao Feng,Eric P. Winer +31 more
TL;DR: In heavily pretreated patients with HER2-positive metastatic breast cancer, including those with brain metastases, adding tucatinib to trastuzumab and capecitabine resulted in better progression-free survival and overall survival outcomes than adding placebo.
Journal ArticleDOI
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
Seock-Ah Im,Yen-Shen Lu,Aditya Bardia,Nadia Harbeck,Marco Colleoni,Fabio Franke,Louis W.C. Chow,Joohyuk Sohn,Keun-Seok Lee,Saúl Campos-Gómez,Rafael Villanueva-Vazquez,Kyung Hae Jung,Arunava Chakravartty,Gareth Hughes,Ioannis Gounaris,Karen Rodriguez-Lorenc,Tetiana Taran,Sara A. Hurvitz,Debu Tripathy +18 more
TL;DR: This trial showed significantly longer overall survival with a CDK4/6 inhibitor plus endocrine therapy than with endocrine Therapy alone among patients with advanced hormone-receptor-positive, HER2-negative breast cancer.
Journal ArticleDOI
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
Debu Tripathy,Seock-Ah Im,Marco Colleoni,Fabio Franke,Aditya Bardia,Nadia Harbeck,Sara A. Hurvitz,Louis W.C. Chow,Joohyuk Sohn,Keun Seok Lee,Saúl Campos-Gómez,Rafael Villanueva Vazquez,Kyung Hae Jung,K Govind Babu,Paul Wheatley-Price,Michelino De Laurentiis,Young-Hyuck Im,Sherko Kuemmel,Nagi S. El-Saghir,Mei Ching Liu,Gary Carlson,Gareth Hughes,I Diaz-Padilla,C. Germa,Samit Hirawat,Yen-Shen Lu +25 more
TL;DR: In this paper, ribociclib plus endocrine therapy showed improved progression-free survival compared with letrozole alone as first-line treatment for postmenopausal patients with hormone receptor (HR)-positive, HER2-negative, advanced breast cancer.